-
公开(公告)号：EP2287310B1
公开(公告)日：2015-05-06
申请号：EP10179665.4
申请日：2005-07-21
发明人： Behrens, Dirk , Bosch, Elizabeth , Doberstein, Steven , Halenbeck, Robert, Forgan , Hestir, Kevin , Huang, Min, Mei , Lee, Ernestine , Lin, Haishan , Linnemann, Thomas , Marshall, Shannon , Wong, Justin, G., P. , WU, Ge , Zhou, Aileen , Leo, Cindy , Williams, Lewis, T.
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
-
公开(公告)号：EP1778842B1
公开(公告)日：2012-01-11
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
3.发明公开Compositions and methods of use for mgd-csf in disease treatment 有权Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
公开(公告)号：EP2287310A1
公开(公告)日：2011-02-23
申请号：EP10179665.4
申请日：2005-07-21
发明人： Behrens, Dirk , Bosch, Elizabeth , Doberstein, Steven , Halenbeck, Robert, Forgan , Hestir, Kevin , Huang, Min, Mei , Lee, Ernestine , Lin, Haishan , Linnemann, Thomas , Marshall, Shannon , Wong, Justin, G., P. , WU, Ge , Zhou, Aileen , Leo, Cindy , Williams, Lewis, T.
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： The present invention relates to in vitro methods for stimulating, or increasing a population of, immune cells comprising using compositions which comprise a substantially pure polypeptide comprising a first amino acid sequence having at least about 70% homology to a sequence selected from SEQ. ID. NOs:7, 8, 9, and 11; or a biologically active fragment of any of these, wherein said polypeptide or fragment thereof can stimulate the proliferation and differentiation of granulocytes, monocytes, or dendritic cells; and to the use of these polypeptides in methods of treatment
摘要翻译： 本发明涉及用于刺激或增加免疫细胞群体的体外方法，其包括使用包含基本上纯的多肽的组合物，所述组合物包含与选自SEQ ID NO：1的序列具有至少约70％同源性的第一氨基酸序列。 ID。 NO：7,8,9和11; 或任何这些的生物活性片段，其中所述多肽或其片段可以刺激粒细胞，单核细胞或树突状细胞的增殖和分化; 以及这些多肽在治疗方法中的用途
-
4.发明公开
公开(公告)号：EP1910542A2
公开(公告)日：2008-04-16
申请号：EP06800260.9
申请日：2006-07-24
发明人： WILLIAMS, Lewis, T. , BOSCH, Elizabeth , DOBERSTEIN, Stephen , HESTIR, Kevin , HOLLENBAUGH, Diane , LEE, Ernestine , QIN, Minmin , SADRA, Ali , WONG, Justin , WU, Ge , ZHANG, Hongbing
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
5.发明公开METHODS OF AND COMPOSITIONS FOR STIMULATION OF GLUCOSE UPTAKE INTO MUSCLE CELLS AND TREATMENT OF DISEASES 审中-公开方法和组合物肌肉刺激的葡萄糖摄取和治疗疾病的
公开(公告)号：EP1890722A2
公开(公告)日：2008-02-27
申请号：EP06760525.3
申请日：2006-05-30
发明人： LIN, Junyu , KOTHAKOTA, Srinivas , WU, Ge , DOBERSTEIN, Stephen , BRENNAN, Thomas , MASUOKA, Lorianne , QIN, Minmin , MARSHALL, Shannon , WANG, Yan , HOLLENBAUGH, Diane , WILLIAMS, Lewis, T.
IPC分类号： A61K38/20
CPC分类号： A61K38/1883 , A61K31/155 , A61K31/18 , A61K31/195 , A61K31/197 , A61K38/1808 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/60 , A61K2300/00
摘要： The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.
-
公开(公告)号：EP1778842B8
公开(公告)日：2012-03-21
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
-
7.发明授权
公开(公告)号：EP1910542B1
公开(公告)日：2009-12-02
申请号：EP06800260.9
申请日：2006-07-24
发明人： WILLIAMS, Lewis, T. , BOSCH, Elizabeth , DOBERSTEIN, Stephen , HESTIR, Kevin , HOLLENBAUGH, Diane , LEE, Ernestine , QIN, Minmin , SADRA, Ali , WONG, Justin , WU, Ge , ZHANG, Hongbing
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
公开(公告)号：EP1778842A2
公开(公告)日：2007-05-02
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C12N15/27
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
